Electrophysiological Outcomes After Transcatheter Aortic Valve Replacement

The TAVR-ELECTRO Registry (Electrophysiological Outcomes After Transcatheter Aortic Valve Replacement) is a single-center, observational cohort study designed to systematically evaluate the occurrence, temporal evolution, and determinants of cardiac arrhythmias following transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis.

This registry retrospectively enrolls consecutive patients undergoing TAVR at Fuwai Hospital, Chinese Academy of Medical Sciences, and collects comprehensive clinical, echocardiographic, electrocardiographic, and procedural data. Particular emphasis is placed on post-procedural electrophysiological outcomes, including ventricular arrhythmias, atrial arrhythmias, and conduction disturbances. Serial rhythm assessments using standard electrocardiography and ambulatory electrocardiographic monitoring are performed during follow-up to characterize arrhythmic burden and its dynamic changes over time.

The primary objective of the TAVR-ELECTRO Registry is to identify clinical, haemodynamic, and procedural factors associated with post-TAVR arrhythmic outcomes and recovery patterns, thereby improving the understanding of electrophysiological remodeling after TAVR and informing post-procedural risk stratification and management strategies.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Aortic Valve Stenosis Aortic Valve Disease Arrhythmia Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Heart Valve Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Ventricular Outflow Obstruction

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences

Beijing, 100037, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥18 years at the time of transcatheter aortic valve replacement (TAVR). Diagnosis of severe aortic stenosis based on current guideline-recommended echocardiographic criteria.

Undergoing transcatheter aortic valve replacement (TAVR) as part of routine clinical care.

Availability of baseline electrocardiographic assessment, including ambulatory electrocardiographic monitoring for evaluation of premature ventricular contraction (PVC) burden.

Completion of post-procedural rhythm follow-up, including ambulatory electrocardiographic monitoring at 12 months after TAVR.

Ability to provide informed consent or availability of legally authorized consent, as required by the institutional review board.

Exclusion criteria

Absence of premature ventricular contractions at baseline (PVC burden = 0), as PVC response cannot be meaningfully assessed in this population.

Presence of a permanent pacemaker or implantable cardioverter-defibrillator prior to TAVR.

Receipt of catheter ablation for atrial or ventricular arrhythmias before TAVR or during the follow-up period.

Death occurring during the index hospitalization or before completion of rhythm follow-up.

Inability to complete scheduled electrocardiographic or ambulatory rhythm assessments during follow-up.

Missing or incomplete key electrocardiographic, echocardiographic, or follow-up data required for outcome assessment.

Treatment and study plan

TAVR Aspirin and clopidogrel

Procedure

This is an observational registry study. All participants undergo transcatheter aortic valve replacement (TAVR) as part of standard clinical care for severe aortic stenosis. The choice of valve type (balloon-expandable or self-expanding), valve brand, valve size, access route, and peri-procedural management strategies are determined by the local heart team according to current clinical guidelines and routine practice.

No additional investigational intervention is mandated by the registry protocol. The study does not alter clinical decision-making, procedural techniques, or post-procedural treatment strategies. Instead, the registry systematically collects clinical, echocardiographic, electrocardiographic, and procedural data before and after TAVR to evaluate electrophysiological outcomes.

Post-procedural rhythm assessment, including standard electrocardiography and ambulatory electrocardiographic monitoring, is performed as part of routine follow-up care. Data on ventricular arrhythm

Primary outcomes

Premature Ventricular Contraction (PVC) Response at 12-Month Follow-up

Time frame: Baseline to 12 months after transcatheter aortic valve replacement (TAVR)

PVC response is defined as a reduction of ≥50% in premature ventricular contraction burden at 12 months compared with baseline. PVC burden is quantified as the total number of premature ventricular contractions per 24 hours, assessed by 24-hour ambulatory electrocardiographic monitoring. Patients without detectable PVCs at baseline are excluded from the primary responder analysis.

Sponsors and collaborators

Lead sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

Other

Registry information

Acronym: TAVR-ELECTRO

Important dates

Study start: 2022
Primary completion: 2026
Study completion: 2026
First posted: Feb 5, 2026
Registry last updated: Feb 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting